Welcome to our dedicated page for MacroGenics news (Ticker: MGNX), a resource for investors and traders seeking the latest updates and insights on MacroGenics stock.
MacroGenics, Inc. develops antibody-based therapeutics for cancer, with pipeline work built around monoclonal antibodies, DART and TRIDENT multi-specific molecules, and antibody-drug conjugates. Company news commonly covers clinical and regulatory updates for lorigerlimab, MGC026 and MGC028, including FDA communications tied to study conduct and safety monitoring.
Updates also address financial results, capital-resource commentary, strategic collaborations and licensing economics, including royalty interests tied to ZYNYZ (retifanlimab-dlwr), a PD-1 inhibitor originally developed by MacroGenics and licensed to Incyte.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on antibody-based cancer therapies, announced its management's participation in several upcoming investor conferences. Key events include:
- Stifel 2023 Targeted Oncology Days: Presentation by Scott Koenig on April 26, 2023, at 2:00 pm ET.
- H.C. Wainwright BioConnect Investor Conference: Fireside chat with Scott Koenig on May 2, 2023, at 1:00 pm ET.
- JMP Securities Life Sciences Conference: Fireside chat with Scott Koenig on May 15, 2023, at 9:30 am ET.
Investors can access webcasts of these presentations in the Investor Relations section of MacroGenics' website, with archived replays available for 30 days. The company utilizes advanced antibody technology to develop innovative therapeutics.
MacroGenics, Inc. (NASDAQ: MGNX) announced a $15 million milestone payment from Incyte following FDA approval of ZYNYZ™ (retifanlimab-dlwr), a monoclonal antibody for treating Merkel cell carcinoma. Originally developed by MacroGenics and licensed to Incyte in October 2017, ZYNYZ's approval marks the third product launch from MacroGenics' pipeline. Additionally, MacroGenics stands to gain up to $320 million in remaining development and regulatory milestones, $330 million in commercial milestones, and a 15% to 24% royalty on global net sales. The CEO expressed satisfaction over this development, highlighting its significance for patient treatment options.